Brokerages Expect Cooper Companies Inc (COO) to Post $2.96 Earnings Per Share
Wall Street analysts expect Cooper Companies Inc (NYSE:COO) to report $2.96 earnings per share (EPS) for the current quarter, according to Zacks. Ten analysts have issued estimates for Cooper Companies’ earnings. The highest EPS estimate is $3.03 and the lowest is $2.92. Cooper Companies reported earnings of $2.65 per share in the same quarter last year, which indicates a positive year over year growth rate of 11.7%. The business is scheduled to report its next quarterly earnings report after the market closes on Thursday, December 6th.
On average, analysts expect that Cooper Companies will report full-year earnings of $11.61 per share for the current financial year, with EPS estimates ranging from $11.56 to $11.68. For the next financial year, analysts expect that the business will post earnings of $12.26 per share, with EPS estimates ranging from $11.94 to $12.75. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Cooper Companies.
Cooper Companies (NYSE:COO) last issued its earnings results on Thursday, August 30th. The medical device company reported $3.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.07 by ($0.07). Cooper Companies had a return on equity of 17.53% and a net margin of 5.23%. The firm had revenue of $660.00 million during the quarter, compared to the consensus estimate of $653.44 million.
COO stock traded up $3.15 on Thursday, reaching $257.21. The company’s stock had a trading volume of 284,900 shares, compared to its average volume of 394,950. Cooper Companies has a 12-month low of $216.47 and a 12-month high of $280.10. The firm has a market capitalization of $12.86 billion, a price-to-earnings ratio of 26.52, a PEG ratio of 1.98 and a beta of 0.75. The company has a quick ratio of 1.54, a current ratio of 2.58 and a debt-to-equity ratio of 0.70.
In other Cooper Companies news, VP Randal Golden sold 1,731 shares of the firm’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $275.86, for a total transaction of $477,513.66. Following the completion of the transaction, the vice president now owns 1,154 shares of the company’s stock, valued at $318,342.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director A Thomas Bender sold 7,150 shares of the firm’s stock in a transaction on Monday, September 24th. The shares were sold at an average price of $269.36, for a total value of $1,925,924.00. Following the transaction, the director now directly owns 18,355 shares of the company’s stock, valued at approximately $4,944,102.80. The disclosure for this sale can be found here. Insiders sold 80,809 shares of company stock valued at $20,740,667 in the last ninety days. 1.60% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA lifted its position in Cooper Companies by 11.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,054,418 shares of the medical device company’s stock valued at $719,163,000 after buying an additional 323,559 shares during the period. Janus Henderson Group PLC lifted its position in Cooper Companies by 23.8% during the second quarter. Janus Henderson Group PLC now owns 2,618,690 shares of the medical device company’s stock valued at $616,595,000 after buying an additional 502,783 shares during the period. Frontier Capital Management Co. LLC lifted its position in Cooper Companies by 13.5% during the third quarter. Frontier Capital Management Co. LLC now owns 937,389 shares of the medical device company’s stock valued at $259,797,000 after buying an additional 111,828 shares during the period. FIL Ltd lifted its position in Cooper Companies by 16.1% during the third quarter. FIL Ltd now owns 815,901 shares of the medical device company’s stock valued at $226,127,000 after buying an additional 113,054 shares during the period. Finally, Bessemer Group Inc. lifted its position in Cooper Companies by 0.8% during the third quarter. Bessemer Group Inc. now owns 761,555 shares of the medical device company’s stock valued at $211,064,000 after buying an additional 5,828 shares during the period.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
See Also: Trading Strategy Examples and Plans
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.